ACTRN12621000208808招募中2 期
Effect of SGLT2 Inhibition With Empagliflozin on Atrial Fibrillation Severity in overweight adults (SWEET-AF)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •At least 18 years of age
- •Symptomatic paroxysmal or persistent AF (in sinus rhythm at time of enrolment)
- •Body mass index (BMI) > 27
- •NB: A history of diabetes is not required for inclusion
排除标准
- •Current or prior use of SGLT2 inhibitor
- •Not on stable glucose-lowering regimen for 12 weeks if diabetic
- •Estimated glomerular filtration rate < 30ml/min/1.73m2
- •Acute, decompensated heart failure
- •Women pregnant, nursing, or who plan to become pregnant during trial period
- •Contraindication to CMR (implanted cardiac devices, cochlear implants, intracranial metallic implants and claustrophobia).
- •Inability to provide informed consent
研究者
相似试验
尚未招募
3 期
Impact of empagliflozin on nephrolithiasis among patients without diabetes compared to a placebo in reduction in the number and/or size of renal stonesephrolithiasisSLCTR/2023/012Professorial Medical Unit
进行中（未招募）
1 期
Empagliflozin reduces progression of diabetic retinopathy in patients with high risk of diabetic macular edemaEUCTR2016-000825-38-DEHannover Medical School80
进行中（未招募）
1 期
SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and lipid content of myocardium (EMPATROPHY)Patients with type 2 diabetes mellitus on background metformin treatment.MedDRA version: 18.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-003313-28-DEHannover Medical School60
进行中（未招募）
1 期
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesEUCTR2018-001569-17-NLRadboud university medical center15
已完成
2 期
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424DiabetesNL-OMON48616Radboud Universitair Medisch Centrum15